MAPT and Alzheimer disease: -The combination of VEGF levels, the three classical CSF biomarkers of AD (Aβ1-42, T-tau, and p-tau), and another marker (heart-type fatty acid binding protein) displayed sensitivity of 82.61% and a specificity of 85.71% to distinguish between AD and control subjects.